Powered By
I received this information on ni006, which shows signs of removing Attr amyloid from the system. Phase I was completed earlier this year.
“The drug is moving directly to Phase 3 studies
A phase 3 trial will begin by the end of the year/beginning 2024. The company who has acquired the drug and is running the phase 3 is Alexion.
Enrollment for the Phase 3 trial will be worldwide including the US. I recommend to contact alexion US or a local specialist in cardiac amyloidosis to identify a… read more
i am not eligible because o have sclerosis of the liver
Thanks for the information God Bless
There’s some hopeful treatments on the horizon. Prayers that they’re approved and affordable!
I will be looking at the study.
interesting. I think when someone sends a message they should tell what type of Amylodosis they have as they are very different.
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
